Taiho Pharmaceutical Co., Ltd.
↗Tokyo, Japan
Taiho Pharmaceutical is an R&D-driven specialty pharmaceutical company headquartered in Tokyo, Japan, and a wholly owned subsidiary of Otsuka Holdings Co., Ltd. The company focuses primarily on oncology and immune-related diseases, leveraging proprietary drug discovery platforms such as Cysteinomix and fragment-based drug discovery.
Beyond its core oncology business, Taiho operates a consumer healthcare division. The company maintains a global presence with R&D and commercial operations in Japan, the U.S., Europe, and Asia, aiming to deliver innovative treatments to patients worldwide.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:¥215.6 billion (FY2025)
Founded:1963
Ownership:subsidiary
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, ADC, Cell therapy
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Otsuka Holdings Co., Ltd.
Acquired By:Otsuka Holdings Co., Ltd.
Subsidiaries:Taiho Oncology, Inc., Taiho Pharma Canada, Inc., Taiho Pharma Europe Limited, Taiho Ventures, LLC, Taiho Innovations, LLC
Key Partnerships:Cullinan Therapeutics (Zipalertinib development), Merck (KRAS G12C inhibitor collaboration), Arcus Biosciences, Haihe Biopharma
COMPETITION
Position:Leader
Competitors:Roche, Merck, Bristol-Myers Squibb, Amgen
LEADERSHIP
Key Executives:
Masayuki Kobayashi - President and Representative Director
Atsushi Azuma - Managing Director
Peter Melnyk - President & CEO, Taiho Oncology, Inc.
LINKS
Website:taiho.co.jp
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Taiho Pharmaceutical Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Taiho Pharmaceutical Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.